• 31

    October

    Novo Nordisk invests DKK 750 million in new laboratories for diabetes research in Denmark ... Read more

    30

    October

    Increased operating profit in local currencies by 11% in the first nine months of 2014 ... Read more

  • 31

    October

    Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

    30

    October

    Increased operating profit in local currencies by 11% in the first nine months o ... Read more

    29

    October

    Share repurchase programme ... Read more

    20

    October

    Share repurchase programme ... Read more

Contact Media

If you have any questions, please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices

Contact Media Relations

Financial results: Increased operating profit in local currencies by 11%

30 October - Sales increased by 8% in local currencies and by 4% in Danish kroner to DKK 64.2 billion during the first nine months of 2014 compared to the same period in 2013. Lars Rebien Sørensen, CEO: “We are satisfied with the financial results for the first nine months of 2014. In the US, Levemir® continues to perform well, and with the approval of Xultophy® in Europe we now look forward to launching this product in the first half of 2015.”

Read the company announcement

See the interview with CFO Jesper Brandaard on CNBC

 

Xultophy® (IDegLira) approved in Europe

18 September - The European Commission has granted marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. The authorisation covers all 28 European Union member states. Xultophy® is the brand name for IDegLira, the first once-daily single injection combination of Tresiba® and Victoza®. Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk said, “We believe that Xultophy® represents a new paradigm with the potential to transform how type 2 diabetes is treated. We look forward to making the product available to people with type 2 diabetes in Europe.”

Read the company announcement

Saxenda® for the treatment of obesity receives 14-1 vote in favour of approval

11 September - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda®, the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity.

The panel members voted 14-1 that the overall benefit-risk assessment Saxenda® was favourable and supports approval for chronic weight management in individuals with a BMI 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of at least one weight-related comorbidity. “We look forward to working with the FDA as they complete their review of Saxenda®. Obesity is a serious public health issue in the US and we are committed to making Saxenda® a new treatment option for adults with obesity.” 

Read the full announcement 

Copenhagen joins 'Cities Changing Diabetes'

Copenhagen, Denmark, 22 August 2014 – Today, the City of Copenhagen and Novo Nordisk announces an ambitious partnership to fight the diabetes challenge in Copenhagen. The partnership is a part of the global ‘Cities Changing Diabetes’ programme, which was initiated by Novo Nordisk and first launched in Mexico City on 28 March 2014. “On a global level we know that two in three of all people with diabetes live in cities. With ‘Cities Changing Diabetes’ we hope to get cities around the world to work together to find sustainable solutions to the urban diabetes challenge. We are very pleased that Copenhagen has decided to join. In Denmark, around 89% of people with diabetes live in cities, so we hope that the solutions we find in Copenhagen can also inspire other cities in Denmark", says Lars Rebien Sørensen, CEO of Novo Nordisk.

See the release

Clinical Trial Transparency

1 March - Novo Nordisk has made it easier for external researchers to get access to clinical trial data. You may read about how we conduct our clinical trials, about volunteering to participate, how we disclose trial information to the public and how researchers can access clinical trial datasets.
Read more about clinical trials.

Calendar

World Diabetes Day

14

November

Worldwide


Growth challenges

11 September - Read about the interaction between growth businesses and public-sector research and education. What challenges must be solved in order for research-based businesses to continue to grow in Denmark? Download the analysis in Danish or English. 

TBL Quarterly

25 September - Beyond conflict: Putting the focus on health in the Middle East. Read the stories in the new TBL Quarterly.  

Novo Nordisk Stories

Changing Diabetes in India

11 June - In India, there are not enough healthcare professionals to meet the needs of the 65 million people with diabetes. Partnerships can change this. Find out how (PDF)